CFO Departs Due to HR Violation; Interim CFO Appointed
MPLT has more than doubled off its 52-week low of $12.24 on elevated volume (4.6× avg).
Summary
MapLight Therapeutics announced the immediate separation of its Chief Financial Officer due to a human resources violation, appointing its Chief Administrative and Accounting Officer as interim CFO.
Key Events · Executive and Board Changes · MPLT
-
Chief Financial Officer Departs
Vishwas Setia was separated as the Chief Financial Officer of MapLight Therapeutics, Inc., effective immediately.
-
Reason for Separation
The departure followed a review of a human resources violation. The company clarified it was unrelated to financial or operating results, internal controls, or clinical programs.
-
Interim CFO Appointed
Jonathan Gillis, the company's Chief Administrative and Accounting Officer, was appointed interim Chief Financial Officer and interim principal financial officer.
-
Severance Terms
Mr. Setia is not entitled to severance payment but will receive continued health coverage under COBRA for up to three months as part of a separation agreement.
Analysis · MPLT · Life Sciences
The immediate separation of a Chief Financial Officer due to a human resources violation represents a notable disruption in executive leadership. While the company explicitly stated the departure was unrelated to financial performance or controls, the underlying reason for the separation is a negative signal regarding internal conduct. The appointment of an internal Chief Administrative and Accounting Officer as interim CFO provides some continuity during this transition.
How filings like this one have moved
In the 30 days to Sep 18, 2026, 29.1% of the 1692 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.38%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MPLT was trading at $28.82 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $12.24 to $33.28. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.